Dr. Lopez Chavez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
314 E. North Avenue
Level 1
Pittsburgh, PA 15212Phone+1 412-325-5700Fax+1 833-645-2173
Summary
- Board certified medical oncologist specializing in thoracic malignancies. Trained at the National Cancer Institute and then lead the lung cancer clinical and research programs at the Oregon Health and Science University's Knight Cancer Institute in Portland, OR and at the University of Miami, Sylvester Comprehensive Cancer Center. From 2015 to 2022 I was a Medical Director and Global Head of Oncology Strategic Innovations at Roche / Genentech.
I am currently the Director of Precision Medicine and Developmental Therapeutics at the Allegheny Health Network Cancer Institute.
Clinical Expertise
- Lung cancer, Personalized medicine, Thoracic oncology, Developmental Therapeutics, General medical oncology, Precision Medicine
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
- UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
- Universidad Nacional Autonoma de MexicoMS, Neurobiology, 2002 - 2005
- OtherClass of 2002
- Centro de Computacion Professional de MexicoBachelor's, Computer Programming, 1993 - 1995
Certifications & Licensure
- CA State Medical License 2017 - 2025
- PA State Medical License 2008 - 2024
- OR State Medical License 2010 - 2021
- FL State Medical License 2014 - 2018
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Publications & Presentations
PubMed
- 31 citationsRandomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V. Sequist, Jhanelle E. Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele
The Oncologist. 2019-08-01 - 1933 citationsFirst-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S. Mansfield, Aleksandra Szczesna, Libor Havel, Maciej Krzakowski
The New England Journal of Medicine. 2018-09-25 - 2430 citationsAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy
The New England Journal of Medicine. 2018-06-04
Journal Articles
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket TrialLopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Be..., J Clin Oncol, 1/9/2015
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):...Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zal..., Lancet Oncol, 1/1/2015
- Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancerSullivan DR, Ganzini L, Lopez-Chavez A, Slatore CG, Psycho-Oncology, 1/28/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-sma...David E. Gerber, Suresh S. Ramalingam, Daniel Morgensztern, Ronan Joseph Kelly, Timothy Francis Burns, Ariel Lopez-Chavez, David R. Spigel, Ahmad Mouhamad Wehbe, Rache..., Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts, 1/20/2014
- A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.Lecia V. Sequist, Ariel Lopez-Chavez, Robert Charles Doebele, Jhanelle Elaine Gray, Wael A. Harb, Manuel R. Modiano, David Michael Jackman, Maria Quintos Baggstrom, Ak..., Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts, 1/1/2014
- Join now to see all
Lectures
- Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies, The CUSTOM trial experience.Miami, FL - 1/1/2013
- Tarceva and Avastin in Lung Cancer.Boise, ID - 1/17/2012
- An Evolving Treatment Strategy for Advanced Nonsquamous NSCLC with ALIMTA.Hood River, OR - 1/8/2012
- Join now to see all
Other
- Cancer de Mama: Que es la neuropatia?Lopez-Chavez, A., SisaludTV
www.youtube.com
1/26/2013 - Cancer de Mama: Efectos adversos communes de la quimioterapia.Lopez-Chavez, A., SisaludTV
www.youtube.com
1/26/2013 - Cancer de Mama: Como se de la quimioterapia?Lopez-Chavez, A., SisaludTV
www.youtube.com
1/26/2013 - Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: